natgillin/translations-raw huggingface dataset:
In an even more specific embodiment, the compound is selected from Compound 114, Compound 120, Compound 122 and Compound 131. 
Spoj prema zahtjevu 2, gdje se spoj bira od spoja 114, spoja 120, spoja 122 i spoja 131 ili farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih spojeva.
The peptide-derived molecule according to claims 1 to 3 having the amino acid sequence of SEQ.ID NO. I., SEQ.ID NO.2., SEQ.ID NO.3 or SEQ.ID NO.4. 
Molekula izvedena iz peptida prema zahtjevima 1 do 3, naznačena time da ima sekvencu aminokiselina koja se bira iz skupine koja se sastoji od:
and R21, taken together with the nitrogen atom to which they are attached, form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; 
Ri R"', zajedno s atomom dušika za koji su vezani, formiraju heterociklični prsten s 5-6 članova koji sadrži 1-2 heteroatoma izabrana 12 grupe koju čine N 1 O;
The solid pharmaceutical composition of claim 1, wherein said solid pharmaceutical composition disintegrates within 30 seconds. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 2, naznačeno time da se navedena tableta rastapa unutar 30 sekundi.
Preferably, the humidity content of the dried veneer is below 80 %, more preferred below 60 %, still more preferred below 40 %. 
Poželjno je da je sadržaj vlage furnira koji se suši ispod 80%, još poželjnije ispod 60 %, i još više poželjno ispod 40 %.
The dosing interval may be about every five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen days or longer. The dosing interval may be at least about one and one-half to 5, one and one-half, 2, 3, 4, or 5 days or longer. 
Kimerni polipeptid, namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je interval doziranja jednom u svakih 3-5, 3-6, 3-7, 3, 4, 5, 6, 7 ili 8 dana.
The dosage form according to claim 6, characterized in that it is suitable for oral, intravenous, intraarterial, intraperitoneal, intradermal, transdermal, intrathekal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration. 
Oblik doziranja prema zahtjevu 8, naznačen time da je pogodan za oralnu, intravenoznu, intraarterijalnu, intraperitonealnu, intradermalnu, transdermalnu, intratekalnu, intramuskularnu, intranazalnu, transmukoznu, subkutanu, ili rektalnu primjenu.
After 15 minutes, a solution of di-tert-butyl dioxalate (3.73 g, 18.5 mmol) in THF (15 mL) was added. 
Nakon 15 minuta, dodana je otopina di-terc-butil dioksalata (3.73 g, 18.5 mmol) u THF (15 mL).
The method according to claim 3, further comprising administering the reconstituted pharmaceutical product to a patient through an administration port disposed in the flexible bag. 
Postupak u skladu patentnim zahtjevom 4, naznačen time, da nadalje obuhvaća davanje konačnog farmaceutskog proizvoda pacijentu kroz otvor za davanje (124) koji se nalazi u fleksibilnoj vrećici (100).
When the reagent used is a carboxylic acid, an exemplary procedure (as shown in FIG. 18) is as follows. 
Kada je reagens koji se koristi karboksilna kiselina, slijedi postupak koji je prikazan kao primjer (kao što je prikazano na slici 18).
An adhesive composition according to any one of claims 2 to 6, wherein (iii) is a hydroxyacrylate, and optionally hydroxyethylacrylate; or wherein (iii) is a hydroxyl(meth)acrylate, optionally selected from a polyethylene glycol methacrylate and polypropylene glycol methacrylate. 
Sastav ljepila prema bilo kojem od zahtjeva 2 do 9, naznačen time, da (iii) je hidroksil(met)akrilat, poželjno odabran od polietilen-glikol-metakrilata i polipropilen-glikol-metakrilata.
It is then concentrated under reduced pressure and the residue is quenched with water (10 mL). 
To se zatim koncentrira pod sniženim tlakom, a ostatak ugasi vodom (10 ml).
or an activated derivative thereof with the amine NH R4R5 wherein NR4R5 has the meaning defined in formula (I) under standard conditions for preparing amides from a carboxylic acid or a mixed anhydride thereof and an amine HNR4R5. 
(11) ili njenog aktiviranog derivata s aminom NHR4Rs, gdje NRARs znači kao što je definirano za formulu (1), u standardnim uvjetima dobivanja amida iz karboksilne kiseline ili njenog miješanog anhidrida i amina HNR4ARs.
Roofing or wall covering having a plurality of rows of roofing or wall covering elements which adjoin one another and are laid in an overlapping manner, at least some of the roofing or wall covering elements being fastened or being capable of being fastened mechanically in a reversibly releasable manner to the roof or wall substructure by way of the respective complementary fastening element which is attached or can be attached to a roof or wall substructure and/or the underlying roofing or wall covering element, the complementary fastening elements being provided by a clip according to any one of the claims 5 to 8. A roofing or wall covering according to claim 12, wherein at least some of the roofing or wall covering elements being roofing or wall covering elements according to any one of the claims 1 to 4. 
Krovni ili zidni pokrov koji ima mnoštvo redova krovnih elemenata ili elemenata zidne obloge (1) koji graniče jedni s drugima i postavljaju se na preklapajući način, barem neki krovni elementi ili elementi zidne obloge su učvršćeni ili su sposobni da ih se pričvrsti na mehanički na povratno oslobodiv način na podstrukturu krova ili zida (4) pomoću odgovarajućeg komplementarnog elementa za učvršćivanje (6, 9) koji je priključen ili može biti priključen na podstrukturu krova ili zida i/ili temeljni krovni element ili element zidne obloge, navedeni barem neki krovni elementi ili elementi zidne obloge su krovni elementi ili elementi zidne obloge za postavljanje na preklapajući način s drugim krovnim elementima ili elementima zidnih obloga, te navedeni krovni elementi ili elementi zidnih obloga sadrže o prvu površinu za osiguravanje vanjske površine navedene krovne ili zidne obloge;
The method according to claim 1 or 2, wherein said sialylation pattern is characterised by at least one of the following characteristics: 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni uzorak sijaliliranja ima najmanje jednu od sljedećih značajki:
A compound of formula: 
[image] sa spojem formule (XVII):
an antibody comprising a light chain variable domain of sequence SEQ ID No. 21 or any sequence exhibiting at least 80% identity with SEQ ID No. 21 and the three heavy chain CDRs of sequences SEQ ID Nos. 8, 2 and 3; and 
HR P20190888 T1 d) antitijela koje sadrži varijabilnu domenu lakog lanca sekvencije SEQ ID br. 21 te tri teška lanca CDRs sekvencije SEQ ID br. 8,2 i 3; te e) antitijela koje sadrži varijabilnu domenu lakog lanca sekvencije SEQ ID br. 22 te tri teška lanca CDRs sekvencije SEQ ID br. 7,213.
The results of these experiments are reported in Table I. 
Rezultati ovih eksperimenata navedeni su u Tablici I
C1-C6—X, wherein X is selected from the group consisting of hydroxyl or protected hydroxyl, halogen, and N3; 
-CHO; Ci-C4-X, gdje se X bira iz skupine koju čine hidroksil, halogen, te Ng;
an implantable operation device (90; 42; 54; 40; 217; 218; 452) for operating the stretching device, when implanted, to stretch the stomach wall portion such that satiety is created, characterized in that the operable stretching device is adapted to be placed against the inside of the stomach wall. 
usadljivi uređaj za rukovanje (90; 42; 54; 40; 217; 218; 452), namijenjen rukovanju uređajem za rastezanje kada je usađen, kako bi rastegnulo dio stijenke želuca, tako da se stvori osjećaj sitosti, naznačen time što je upravljivi uređaj za rastezanje prilagođen za stavljanje s vanjske strane stijenke želuca.
Inhibition of Free Fatty-Acid Production, in vivo, in Catheterized Male Sprague-Daly Rats 
Inhibicija produkcije slobodnih masnih kiselina, in vivo, na kateteriziranim muškim Sprague-Daly štakorima
Pharmaceutical forms for administration of the compounds of the Formula (I) as an aerosol can be prepared by processes well-known to the person skilled in the art. 
Farmaceutski oblici za primjenu spojeva Formule (I) kao aerosola se mogu pripremiti postupkom dobro poznatim u struci.
The method according to any one of embodiments 40 to 42, wherein glucose oxidase is glucose oxidase of SEQ ID NO: 10 or a functional homologue thereof sharing at least 70%, such as at least 80%, for example at least 85%, such as at least 90%, for example at least 95% sequence identity therewith. 
Postupak prema bilo kojem od zahtjeva 1 do &, naznačen time što enzim ili smjesa enzima koji su sposobni katalizirati pretvaranje glukoze obuhvaćaju glukozu oksidazu, kao što je glukoza oksidaza iz SEQ ID NO: 10 ili njezin funkcionalni homolog koji ima najmanje 70 %, na primjer najmanje 80 %, na primjer najmanje 85 %, kao što je najmanje 90 %, na primjer najmanje 95 % identičnosti sekvence s njom.
A compound of Formula I′ 
Spoj Formule Ib:
Note that the term “beverage” is meant to also encompass liquid comestibles in the framework of the present specification and the enclosed claims. 
Napominje se da se pod izrazom "napitak" namjerava također obuhvatiti tekuće prehrambene proizvode u okviru predmetnog opisa i priloženih patentnih zahtjeva.
Another embodiment provides a compound of formula (I) wherein M is H. 
Spoj sukladno patentnom zahtjevu 1, naznačeno time, što M je H.
The method of claim 18, wherein steps b) to d) are also carried out on the reverse side of the base layer to manufacture a print medium being coated on the first side and the reverse side. 
Postupak prema zahtjevu 17, pri čemu se koraci b) do d) također provode na stražnjoj strani osnovnog sloja da se proizvede tiskovna podloga koja je premazana na prvoj strani i stražnjoj strani.
This solution was concentrated to ∼ 100 mL and applied to the column. 
Ova otopina je bila koncentrirana do -100 mL i stavljena na stupac.
The gaming system of claim 1, wherein said projected images include chip denominations and account balances. A gaming method comprising: 
Sustav igranja prema patentnom zahtjevu 1, naznačen time da projicirane slike prikazuju oznake čipova i stanje računa.
The screen panel as claimed in claim 1, wherein the crosspieces are made of profiles having an H having two crosspiece channels in line with one another. 
Zaslonska ploča kako je zatraženo u patentnom zahtjevu 1 ili 2, naznačena time što su poprečne grede (3') izrađene od profila različitog tipa, naročito u obliku slova H (10) koji imaju dva kanala (11) u liniji jedan s drugim.
In a preferred embodiment according to the invention, the above-mentioned pharmaceutical composition comprises the (Z,Z)-isomers of the thiazolidin-4-one derivatives of the General Formula (I). 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da spomenuti derivati tiazolidin-4-ona su (Z,Z)-izomeri prema Općoj formuli (I) u zahtjevu 1.
A method for improving crop yields, which comprises applying an effective amount of the acid amide derivative or a salt thereof as defined in any one of the above (1) to (32). 
Postupak za poboljšanje uroda, naznačen time, da uključuje primjenu učinkovite količine derivata amida kiseline formule (I) ili njegove soli, kako je definiran patentnim zahtjevom 1.
Ra and Rb are chosen independently of each other from the group consisting of hydrogen and halogen; 
R*i R? ge, međusobno neovisno, bira iz skupine koju čine vodik i halogen;
A method of transmitting a navigation signal comprising the steps of: 
Postupak odašiljanja navigacijskog signala koji sadrži korake:
providing the plant cultivation system of claim 1, placing a plant on the nonporous hydrophilic film of said plant cultivation system, and 
(2) postavljanje biljke na neporozni hidrofilni sloj (1) tog sustava za uzgoj biljaka, i
The method of claim 6, including the step of impregnating the resin impregnable material by passing the tubular member through a resin bath to impregnate the resin impregnable material with resin. 
Postupak prema zahtjevu 1, naznačen time da uključuje korak impregnacije smolastog impregnirajućeg materijala prolazom cjevastog elementa kroz kupku sa smolom (53) radi impregnacije smolastog impregnirajućeg materijala sa smolom.
Procedure according to claim 10, in which the acidification is performed by adding to the culture at least one acidifying agent selected from the group consisting of CO2, a mixture of CO2 and air, strong or weak acids or any combination of these. 
Postupak u skladu s patentnih zahtjeva 10 ili 11, naznačen time što se zakiseljavanje provodi dodavanjem u kulturu najmanje jednog sredstvo za zakiseljavanje, koje se bira iz skupine koju čine CO», smjesa CO, i zraka, jake ili slabe kiseline ili bilo koja njihova kombinacija.
A capsule for infusion products, the capsule comprising: 
Kapsula (1) za infuzijske proizvode koja se sastoji od:
The peptide according to Claim 3, wherein said fusion protein comprises the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s patentnim zahtjevom 3, pri čemu navedena fuzijska bjelančevina sadrži N-terminalne nos aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
About 0 to about 100 wt % of the total amount of the disintegrant can be present in the granules. 
- otapanje 1 raspršivanje preostalog udjela ukupne količine vezivnog sredstva u granulacijskoj tekućini;
receiving touch point information about a plurality of touch points recognized as multi-touch through the capacitive touch screen; 
drugi korak (1100) primanja podataka točke dodira o pluralitetu prepoznatih točaka dodira kao višestrukih dodira preko kapacitivnog zaslona osjetljivog na dodir;
General methods of organic synthesis and functional group transformations are found in: Trost, B.M. and Fleming, I., eds. Comprehensive Organic Synthesis: Selectivity, Strategy & Efficiency in Modern Organic Chemistry. 
Opći postupci organske sinteze i transformacija funkcionalne skupine pronađeni su u: Trost, B.M. i Fleming, I., urednici Comprehensive Organic Synthesis: Selectivity, Strategy & Efficiency in Modern Organic Chemistry.
Method for deploying a solar panel assembly according to claim 1, wherein the method comprises the steps of: 
Metoda postavljanja sklopa solarnog panela (2) u skladu s patentnim zahtjevom 1, naznačena time što metoda sadrži korake:
compressing the blend from the step (5) into a tablet; and 
komprimiranja smjese iz (5) u tablete;
at least one emetic, 
(d) barem jedan emetik,
A pharmaceutical composition comprising a compound as claimed in either claim 1 or claim 2, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time, da sadrži spoj iz bilo kojeg od patentnih zahtjeva 1 ili 2 1 farmaceutski prihvatljiv nosač.
Additionally, previous, similar experiments that investigated the hydrolysis in whole blood of rapamycin carbohydrate derivatives with carbamate linkages showed little or no hydrolysis in contrast to many of the compounds with carbonate linkages in Table 3. 
Nadalje, prethodni, slični eksperimenti koji su istraživali hidrolizu ugljikohidratnih derivata rapamicina s karbamatnim vezama u punoj krvi pokazali su malo ili nimalo hidrolize, suprotno većini spojeva s karbonatnim vezama iz Tablice 3.
The vaccine of claim 1, wherein the at least two peptide fragments of PCSK9 are coupled to a pharmaceutically acceptable carrier. 
Cjepivo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da su najmanje dva fragmenta od PCSK9 spojena na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
More specifically, one or more amino acids of the proteins, but no more than 30, preferably no more than 20, more preferably no more than 10, most preferably one or two amino acids, may be replaced with other amino acids, or eliminated, or may be added. 
Još specifičnije, može se eliminirati, dodati ili izmjeniti jedna 1li više aminokiselina, ali ne više od njih 30, poželjnije ne više od 20, još poželjnije ne više od 10 1 najpoželjnije jedna ili dvije.
is selected from alkyl, aryl and arylalkyl; by reacting a compound of formula (3), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group; 
R1 vodikova ili dušikova zaštitna grupa; i R4 je odabran od alkila, arila i arilalkila; reakcijom spoja sa formulom (3), ili njegove soli,
Compound 75 was obtained as a white solid from compound 74 and 4-amino-N-thiophen-2ylmethyl-benzamide by method C, followed by treatment with trifluoroacetic acid overnight at room temperature. 
Spoj 75 se dobiva kao bijela krutina iz spoja 74 i 4-amino-N-tiofen-2-ilmetil-benzamida pomoću postupka C, nakon čega slijedi tretman trifluoroctenom kiselinom preko noći na sobnoj temperaturi.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
The method according to claim 1 wherein the carboxylic acid nucleophile is a heteroaromatic acid containing at least one atom of nitrogen. 
Postupak prema patentnom zahtjevu 1 ili 2 naznačen time da je nukleofil karboksilne kiseline heteroaromatska kiselina koja sadrži barem jedan atom dušika.
the first polypeptide and the second polypeptide form an antibody, antibody fragment or Fab fragment, and wherein the first and/or second polypeptide when expressed in a prokaryotic cell is fused to a coat protein selected from the group consisting of pI, pII, pIII, pIV, pV, pVI, pVII, pVIII, pIX and pX of bacteriophage M13, f1 or fd or an adaptor protein selected from the group consisting of SEQ ID NOs: 6 and 7. 
(d) prvi polipeptid i drugi polipeptid tvore protutijelo, fragment protutijela ili Fab fragment; i (e) pritom se prvi i/ili drugi polipeptid, kada se eksprimira u prokariotskoj stanici, spaja s proteinom oblaganja odabranim iz skupine koja se sastoji od Pl, pil, Pill, PIV, PV, PVL PVII, PVIII, piX i pX bakteriofaga M13, f1 ili fd, ili proteina adaptera odabranog iz grupe koja se sastoji od SEKV.
A process for the preparation of compounds of formula (I) 
POSTUPAK ZA PRIPRAVU SPOJEVA KOJI SU KORISNI KAO INHIBITORI SGLT-a
The method of claim 3 wherein the carrier is selected from the group consisting of sugars, fermentation solubles, feed grains, corn cob flour, cellulose, and whey. 
Postupak sukladno patentnom zahtjevu 3 pri čemu je nosač izabran 1z skupine koju čine šećeri, toplivih tvari za fermentaciju, žitarice za hranu, brašno od kukuruznih klipova, celulozu, i druga vlakna drveta, i sirutku
The system according to claim 9, the placing component further comprises a comparing component for comparing the tagged relevant mobile phones with MSISDN numbers that are stored in a priority database, and removing the tag from mobile phones that have its MSISDN stored in the priority database, such that the mobile phones are not prevented from normal communication, in and out from the specific geographical area, while alert messages are being sent. 
Sustav prema zahtjevu 9, naznačen time da dodatno sadrži sredstva za usporedbu označenih odgovarajućih mobilnih telefona, u koraku d), sa MSISDN brojevima pohranjenim u prioritetnoj bazi podataka, te sredstva za uklanjanje oznake s mobilnih telefona koji imaju njihov MSISDN pohranjen u prioritetnoj bazi podataka, tako da oni nisu spriječeni u normalnoj komunikaciji, u i izvan određenog zemljopisnog područja tijekom slanja poruka upozorenja.
The method of claim 10, further comprising shading from solar exposure a portion of the deck and the top portal without obstructing the exposing of the interior region of the cabin to the open-air. 
Metoda iz zahtjeva 9, koju nadalje čini sjenilo koje štiti dio palube (106) i gornjeg portala od izlaganja suncu bez da utječe na izlaganje unutrašnjeg područja gondole (102) atmosferi.
the activated polymer is an activated polyethylene glycol, an activated polydextran, or an activated poly-L-lysine, and 
aktivirani polimer je aktivirani polietilen glikol, aktivirani polidekstran, ili aktivirani poli-L-lizin, te
outcome is breast cancer specific survival, event-free survival, or response to therapy; or 
(1i) ishod je preživljenje specifično za rak dojke, preživljenje bez pojave Traka ili odgovor na terapiju; ili
recycling said deviated part of said second leach solution after said separating of said precipitated calcium carbonate to be used in said step of dissolving at least a part of at least one of said precipitated phosphate compounds and said precipitated aluminium phosphate by an alkaline solution. 
recikliranje (320) spomenutog izdvojenog dijela spomenute druge otopine za ispiranje nakon spomenutog razdvajanja (318) spomenutog istaloženog kalcij karbonata kako bi se koristio u spomenutom koraku otapanja (302) barem dijela barem jednog od spomenutih istaloženih fosfatnih spojeva i spomenutog istaloženog aluminij fosfata alkalnim otapalom.
Bacillus subtilis GN13/72-DSM 17766 is cultured as in Example 4, the antifoam agent being soybean oil. 
Bacillus subtilis GN13/72 - DSM 17766, naznačen time da je položen 5. prosinca 2005. u DSMZ.
wherein the RNA encoding NY-ESO-1 comprises an RNA sequence according to SEQ ID No 21 or being at least 80% identical to SEQ ID No 21, wherein the RNA encoding MAGE-C1 comprises an RNA sequence according to SEQ ID No 24 or being at least 80% identical to SEQ ID No 24, wherein the RNA encoding MAGE-C2 comprises an RNA sequence according to SEQ ID No 26 or being at least 80% identical to SEQ ID No 26, wherein the RNA encoding 5T4 comprises an RNA sequence according to SEQ ID No 4 or being at least 80% identical to SEQ ID No 4, and wherein the RNA encoding Survivin comprises an RNA sequence according to SEQ ID No 19 or being at least 80% identical to SEQ ID No 19, and wherein the G/C content of the coding regions of said RNAs is increased compared to the G/C content of the coding region of the wild-type RNAs, the coded amino acid sequence of said RNAs not being modified compared to the encoded amino acid sequence of the wild-type RNAs. 
* Survivin, HR P20180698 T1 naznačen time da je za RNK koja kodira NY-ESO-I sadrži RNK sekvencu u skladu sa SEQ ID No 21 ili je barem 80% identična sa SEQ ID No 21, pri čemu RNK koja kodira MAGE-C1 sadrži RNK sekvencu u skladu sa SEQ ID No 24 ili je barem 80% identična sa SEQ ID No 24, pri čemu RNK koja kodira MAGE-C2 sadrži RNK sekvencu u skladu sa SEQ ID No 26 ili je barem 80% identična sa SEQ ID No 26, pri čemu RNK koja kodira 5T4 sadrži RNK sekvencu u skladu sa SEQ ID No 4 ili je barem 80% identična sa SEQ ID No 4,1 pri čemu RNK koja kodira Survivin sadrži RNK sekvencu u skladu sa SEQ ID No 19 ili je barem 80% identična sa SEQ ID No 19,1 pri čemu se sadržaj G/C kodirajućih regija navedenih RNK povećava u usporedbi sa sadržajem G/C kodirajućih regija divljih-tipova RNK, kodirane sekvence aminokiselina navedenih RNK nisu modificirane u usporedbi sa kodiranim sekvencama aminokiselina divljih-tipova RNK.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
The pharmaceutical composition of claim 9, which further comprises one or more active substances. 
Farmaceutski pripravak prema patentnom zahtjevu 4, naznačen time da dalje sadrži jednu ili više aktivnih supstanci.